Table 1. Clinical and treatment characteristics of patients with breast cancer who received adjuvant trastuzumab therapy according to cardiotoxicity diagnosis.
| Clinical and treatment characteristics | Cardiotoxicity | p-value | ||
|---|---|---|---|---|
| Yes | No | |||
| Mean ± SD | Mean ± SD | |||
| Age (years) | 54.6 ± 9.8 | 50.8 ± 11.0 | 0.07* | |
| Weight (kg) | 68.7 ± 12.4 | 70.2 ± 14.7 | 0.62* | |
| Body mass index (kg/m2) | 28.4 ± 5.1 | 27.8 ± 5.6 | 0.53* | |
| Cumulative anthracycline dose (mg/m2) | 299.3 ± 59.9 | 289.2 ± 64.9 | 0.49* | |
| Number of cycles of trastuzumab given | 10.8 ± 6.5 | 16.4 ± 2.5 | < 0.001* | |
| Treatment duration for trastuzumab | 9.06 ± 6.5 | 12.2 ± 2.5 | < 0.001* | |
| n(%) | n(%) | p-value | ||
| Dyslipidemia | 3(7.7) | 17(8.0) | 1.00*** | |
| Diabetes mellitus | 5(12.8) | 22(10.2) | 0.58*** | |
| Arterial hypertension | 18(46.1) | 77(35.6) | 0.21** | |
| Smoking status | Yes | 8(20.5) | 26(12.0) | 0.29** |
| No | 26(66.7) | 149(69.0) | ||
| Ex-smoker | 5(12.8) | 41(19.0) | ||
| Age (years) | < 40 | 1(2.6) | 27(12.5) | 0.09*** |
| ≥ 40 | 38(97.4) | 189(87.5) | ||
| Breast side | Right | 16(41.0) | 109(50.4) | 0.27** |
| Left | 23(59.0) | 107(49.5) | ||
| Clinical stage | I | 2(5.1) | 17(7.8) | 0.60** |
| II | 19(48.7) | 88(40.7) | ||
| III | 18(46.1) | 111(51.4) | ||
| Type of chemotherapy | Adjuvant | 29(74.4) | 130(60.7) | 0.10** |
| Neoadjuvant | 10(25.6) | 84(39.3) | ||
| Radiotherapy | Yes | 32(82.0) | 198(92.0) | 0.08*** |
| No | 7(17.9) | 18(8.3) | ||
| Suspension of trastuzumab treatment | Yes | 36(92.3) | 10(4.6) | <0.001** |
| No | 3(7.7) | 206(95.4) | ||
| Permanent interruption of trastuzumab treatment | Yes | 28(71.8) | 5(2.3) | <0.001** |
| No | 11(28.2) | 211(97.7) | ||
| Total: distribution of patients | 39(15.3) | 216(84.7) | 255(100) | |
*
Mann-Whitney test;
**
Chi-square test;
***
Fisher's exact test; SD = standard deviation